HOME
ABOUT THE COMPANY
Company Overview
Message from CEO
Management Team
Enterprise Video
INNOVATION
Pipeline
Focus Areas
Pipeline2
INVESTORS
Fact Sheet
Corporate Governance
Public Disclosure
Financial Report
Announcements and Circulars
Presentations and Webcasts
IR Contact
Analyst List
MEDIA
CONTACT
Contact
Career
菜单
中文
|
EN
HOME
ABOUT THE COMPANY
Company Overview
Message from CEO
Management Team
Enterprise Video
Innovation
Innovation
Pipeline
Focus Areas
Pipeline2
INVESTORS
Fact Sheet
Corporate Governance
Financial Report
Announcements and Circulars
Presentations and Webcasts
Analyst List
IR Contact
MEDIA
CONTACT
Contact
Career
欧康维视提示
本内容仅供医学专业人士使用。如果您是医学专业人士,请点击确认,进入页面;否则请点击退出,返回上一页。
确定
取消
Home
/
Media
Press Release
Media Report
2020
2022
2021
2020
2019
2018
2020-12-01
欧康维视OT-401启动真实世界研究,葡萄膜炎first-in-class药物上市进展有望加速
2020-03-31
Notice Regarding Business Alliance Between SanBio And Ocumension In The Research, Development And Commercialization Of Innovative Stem Cell Therapies For Ophthalmic Diseases
2020-01-27
EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize DEXYCU® for Post-operative Inflammation in Mainland China, Hong Kong, Macau and Taiwan
Follow us